XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborations with Third Parties (Details) - USD ($)
3 Months Ended 12 Months Ended
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Collaborations with Third Parties            
Collaboration revenue       $ 18,836,000 $ 7,978,000  
Collaboration revenue            
Collaborations with Third Parties            
Collaboration revenue       5,482,000 1,628,000  
Daiichi Sankyo Europe GmbH ("DSE") | Royalty revenue and product sales bulk tablets            
Collaborations with Third Parties            
Collaboration revenue       5,300,000 1,600,000  
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement            
Collaborations with Third Parties            
Upfront cash payment received (paid)     $ 150,000,000      
Cash payment to the Company upon first commercial sales in the DSE Territory     $ 150,000,000      
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales     15.00%      
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales     25.00%      
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities            
Collaborations with Third Parties            
Upfront cash payment received (paid)   $ 60,000,000        
Potential additional future payments   $ 450,000,000        
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Collaboration revenue            
Collaborations with Third Parties            
Collaboration revenue       0 $ 0  
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales   15.00%        
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales   30.00%        
Milestone payment, first JNDA submissions   $ 20,000,000        
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000,000        
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000,000        
Milestone payments related to total net sales achievements   $ 310,000,000        
Daiichi Sankyo Co. Ltd            
Collaborations with Third Parties            
Collaboration revenue           $ 28,500,000
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement            
Collaborations with Third Parties            
Collaboration revenue       200,000   28,500,000
Consideration cash payment $ 30,000,000          
Cash payment to be received upon certain commercial milestones $ 175,000,000          
Deferred up-front payment       $ 1,300,000    
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales 5.00%          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales 20.00%          
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, License To Intellectual Property            
Collaborations with Third Parties            
Collaboration revenue           28,000,000
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, Ongoing Regulatory And Development Activities            
Collaborations with Third Parties            
Collaboration revenue           $ 500,000